Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report

Ting Jiang; Chen Gao; Yiyang Luo; Zixiang Ye; Binbin Wang

doi:10.2147/OTT.S369772

Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report

Onco Targets Ther. 2022 Aug 25:15:883-890. doi: 10.2147/OTT.S369772. eCollection 2022.

Authors

Ting Jiang^{1

2}, Chen Gao³, Yiyang Luo⁴, Zixiang Ye⁵, Binbin Wang¹

Affiliations

¹ Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
² Department of Oncology, The First Affiliated Rehabilitation Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
³ Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
⁴ First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
⁵ Peking University China-Japan Friendship School of Clinical Medicine, Beijing, People's Republic of China.

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most fatal diseases, with its morbidity and mortality showing an upward trend. The application of monotonous immune checkpoint inhibitor (ICI) in PDAC comes to a disappointing endpoint, despite of its great advancements achieved in cancer treatment. However, a promising efficacy can be obtained on condition that ICIs are used in combination with chemotherapy.

Case: We reported a patient suffering from metastatic PDAC with proficient mismatch repair (pMMR) and low expression of programmed cell death ligand 1 (PD-L1). The patient survived for a remarkably long time and showed favorable tolerance to the combination of FOLFIRINOX+Toripalimab (a novel PD-1 inhibitor) administrated after chemoradiotherapy and targeted therapy. Today, the survival benefits gained from this therapy will continue to have a positive impact on him.

Conclusion: FOLFIRINOX+Toripalimab potentially serves as a novel therapeutic strategy for PDAC in late stage, with durable benefits and manageable toxicity in patients, which is still required to be validated in further research.

Keywords: chemotherapy; favorable tolerance; long-term survival; pancreatic ductal adenocarcinoma; programmed cell death protein 1.

Publication types

Case Reports

Grants and funding

This work was supported by 2022 National Traditional Chinese Medicine administration Project for the Traditional Chinese Medicine Rehabilitation Service Capability Improvement (No. 2021-242).